Sotera Health Co

Sotera Health Company reported second-quarter revenue of $321.4 million, beating analyst estimates of $309.6 million and growing 9.2% year over year. Adjusted EPS came in at $0.26 versus expectations of $0.24, and adjusted EBITDA reached $165.7 million against a $157.7 million consensus. Management raised full-year revenue guidance to $1.25 billion at the midpoint from $1.24 billion and lifted adjusted EPS guidance to $0.98, a 1% increase. CEO Alton Shader attributed the outperformance to strong demand in Sterigenics and Nordion, improved customer engagement at Nelson Labs, and favorable Cobalt-60 shipment timing. The company also highlighted new X-ray sterilization capacity and a large customer outsourcing sterilization services as catalysts for the second half.

Sotera Health raised its full-year 2026 outlook after reporting second-quarter revenue of $321 million, up 9.2% year over year, or 8% on a constant currency basis. Adjusted EBITDA grew 10% to $166 million, with margins expanding 36 basis points to 51.6%, and adjusted EPS rose 30% to $0.26 per diluted share. The company now expects constant currency revenue growth of 5.25% to 6.75% and adjusted EBITDA growth of 5.75% to 7.25% for 2026, up from prior guidance. Segment performance was broad-based, with Sterigenics delivering 7% constant currency revenue growth, Nordion up 16.7%, and Nelson Labs up 5.4%. CEO Alton Shader, who assumed the role in May, highlighted the company's essential role in healthcare and expressed confidence in the second half, citing stable demand and new capacity coming online.

Waters Corporation delivered the strongest first-quarter performance among the ten research tools and consumables stocks tracked, with revenues of $1.27 billion, up 91.5% year on year and beating analysts' estimates by 4.5%. The company also posted the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Avantor reported revenues of $1.58 billion, flat year on year but exceeding expectations by 2.7%, while Revvity's revenues of $686.9 million, up 9.3% year on year, fell short of estimates by 2.6% and came with full-year guidance that missed expectations. Sotera Health Company posted revenues of $280 million, up 10% year on year and topping estimates by 3.6%, and Bio-Techne reported revenues of $311.4 million, down 1.5% year on year and missing estimates by 1.6%. Overall, the group's revenues beat consensus estimates by 1.3%, and next-quarter revenue guidance was 2% above expectations, with share prices up 22.5% on average since the latest earnings results.

The ten research tools and consumables stocks tracked reported mixed first-quarter results, with aggregate revenues beating analysts' consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Mettler-Toledo posted revenues of 947.1 million dollars, up 7.2% year on year and slightly ahead of estimates, though the quarter was mixed overall. Waters Corporation stood out with revenues of 1.27 billion dollars, a 91.5% year-on-year surge that exceeded estimates by 4.5%, and it delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Revvity's revenues of 686.9 million dollars, up 9.3% year on year, missed estimates by 2.6% and it issued full-year guidance below expectations, marking the weakest performance against estimates in the group. Sotera Health Company reported revenues of 280 million dollars, up 10% year on year and beating estimates by 3.6%, while Bruker's revenues of 823.4 million dollars, up 2.7% year on year, topped estimates by 3.4%. Share prices of the group have risen 20.8% on average since the latest earnings results.

A bullish thesis on Sotera Health Company was published on Valueinvestorsclub.com by AZA0601, arguing the stock is undervalued. The thesis highlights that Sotera Health, an approximately $6 billion enterprise value provider of sterilization solutions, has seen its valuation compress from ~20x to ~10x EBITDA despite solid fundamentals. Revenue grew from $818 million to $1.16 billion and EBITDA from $420 million to $594 million, with duopoly positions, over 90% multi-year contracts, and high switching costs supporting pricing power and high-50% EBITDA margins. Litigation risk has been de-risked through settlements, and management's 5–7% organic growth guidance is viewed as conservative. At ~12x EBITDA less capex, the valuation points to ~$30 per share versus ~$17.10 as of June 25th, implying a ~25% three-year IRR with further upside from regulation, consolidation, and pricing strength.